Navigation Links
Savient Pharmaceuticals Announces Acceptance of Two Gout-Related,Abstracts for Poster Presentation at the European League Against,Rheumatism (EULAR) 2007 Annual Congress

ut Savient's business and the biopharmaceutical and specialty pharmaceutical industries in which Savient operates. Such risks and uncertainties include, but are not limited to, Savient's stock price and market conditions, delay or failure in developing Puricase(R) and other product candidates, difficulties of expanding Savient's product portfolio through in-licensing, introduction of generic competition for Oxandrin(R), fluctuations in buying patterns of wholesalers, potential future returns of Oxandrin or other products, Savient's continuing to incur substantial net losses for the foreseeable future, difficulties in obtaining financing, potential development of alternative technologies or more effective products by competitors, reliance on third-parties to manufacture, market and distribute many of Savient's products, (economic, political and other risks associated with foreign operations) risks of maintaining protection for Savient's intellectual property, risks of an adverse determination in ongoing or future intellectual property litigation, and risks associated with stringent government regulation of the biopharmaceutical industry. Savient may not actually achieve the plans, intentions or expectations disclosed in Savient's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that Savient makes. Stockholders should not place undue reliance on the forward-looking statements, which speak only as to the date of this press release. Savient's forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that Savient may make. Except as required by law, Savient does not assume any obligation to update any forward-looking statements.

SVNT-I

Contact

Savient Pharmaceuticals, Inc.
Mary Coleman, 732-418-9300





Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:10/17/2014)... , Oct. 17, 2014  Ameritox SM , the ... appointment of Thomas Smith , M.D., as Chief ... field-based team offering scientific resources for healthcare providers, patients ... held leadership positions at a variety of healthcare companies ... both the pain and behavioral health sides of Ameritox,s ...
(Date:10/17/2014)...   ndd Medical Technologies , a leader in ... technology, announced that its EasyOne Pro® is now being ... a 140,000 square foot, 44-bed hospital with many outpatient ... serves a large number of Native Americans from several ... and beyond. A portion of its funding comes from ...
(Date:10/17/2014)... , Oct. 17, 2014  STAAR Surgical Company (NASDAQ: ... implantable lenses and delivery systems for the eye, today announced ... Breakfast Meeting on Saturday, October 18, 7:00 a.m. CT at ... Chicago, IL. Dr. Erik ... Centre in Antwerp, Belgium , will present ...
Breaking Medicine Technology:Ameritox Appoints New Chief Medical Officer 2EasyOne Pro Mobile Respiratory Testing from ndd Medical Technologies Chosen by Choctaw Nation 2STAAR Surgical to Webcast Investor Presentations at American Academy of Ophthalmology's Annual Meeting 2STAAR Surgical to Webcast Investor Presentations at American Academy of Ophthalmology's Annual Meeting 3
... Finland, May 29, 2012 Oncos Therapeutics today ... of CGTG-102, an oncolytic adenovirus suggested as a potential new ... have already completed the safety assessment part of the study. ... clinic in No r thern Europe to start ...
... -- Clinilabs, an early phase and specialty CRO ... industry, today announced that they have opened a second ... capacity, 15,000 square foot Specialty Pharma Phase I Unit ... a bioanalytic laboratory, pharmacy, and exam rooms. ...
Cached Medicine Technology:Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers 2Clinilabs Opens Phase I Unit In Eatontown, New Jersey 2
(Date:10/20/2014)... T.E.N., a technology and information security ... William H. Murray, renowned author and industry visionary, ... Award winner. Presented annually, the ISE® Luminary Leadership ... and industry practitioner for his or her distinguished ... security industry. , Formerly with IBM, Murray is ...
(Date:10/20/2014)... Dunbridge, Ohio (PRWEB) October 20, 2014 ... 50 years, takes pride in manufacturing top-of-the-line absorbent products. ... the image of its most popular brand, Tranquility® Premium ... logo, created a new website, gave its packaging a ... to bring the brand message to the public. , ...
(Date:10/20/2014)... CO (PRWEB) October 20, 2014 ... assays are the only imaging assays capable of ... a single test.  With these three dimensions of ... ability to detect the widest range of disease-causing ... usually missed by other genomic tools, including today’s ...
(Date:10/20/2014)... York, NY (PRWEB) October 20, 2014 ... be introduced in the U.S., has a lot to celebrate ... when our country recognizes the achievements and contributions of Americans ... the anniversary for Punzoné, and today it shares its favorite ... take a trip to Italy - even if it is ...
(Date:10/19/2014)... Recently, BambooIndustry.com, one of the most popular suppliers ... bamboo deckings . Moreover, the company has launched ... now available at deeply discounted rates. , As ... overstate the significance of online business nowadays. Thus, BambooIndustry.com ... company’s workers are striving to deliver both value and ...
Breaking Medicine News(10 mins):Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2
... cardiologists have searched for ways to see dangerous blood ... at Washington University School of Medicine in St. Louis ... and make them visible to a new kind of ... a Washington University cardiologist at Barnes-Jewish Hospital, these nanoparticles ...
... unexpected benefit of osteoporosis treatment that people taking ... without osteoporosis, they appear to be gaining an extra ... the Journal of Clinical Endocrinology and Metabolism , ... John Eisman, from Sydney,s Garvan Institute of Medical Research, ...
... German . Lung tumors are the number one ... is lung cancer. Each year, there are 50,000 new cases of ... detected, the greater the chance of healing the patient. But early ... chronic inflammatory reactions. To get a more complete diagnosis, the patient ...
... delivered intranasally, vaccine was found to be more effective, Funding ... PROVIDENCE, R.I. A new study led ... University of Rhode Island (URI) and EpiVax. Inc, a privately ... potential vaccine capable of reducing colonization of Helicobacter pylori ...
... ( www.elsevier.com ), the leading global publisher of ... announced today that it acquired the oncology portfolio ... LP., (operated as Cancer Information Group). The journals ... articles that disseminate cutting-edge data to physicians, medical ...
... HealthDay Reporter , TUESDAY, Feb. 1 (HealthDay News) -- ... blood pressure and cholesterol levels -- both primary risk ... According to the latest report from the U.S. Centers ... have hypertension (high blood pressure), about the same proportion ...
Cached Medicine News:Health News:New nanoparticles make blood clots visible 2Health News:New nanoparticles make blood clots visible 3Health News:An extra 5 years of life an unexpected benefit of osteoporosis treatment 2Health News:Early detection of lung cancer 2Health News:New study identifies potential vaccine to prevent gastritis, ulcer disease, gastric cancer 2Health News:Half of Adults Have Hypertension or High Cholesterol: CDC 2Health News:Half of Adults Have Hypertension or High Cholesterol: CDC 3
Rees bayonet forceps, standard, 5-1/2", TC....
Medpor 2/3 Orbit implants are designed to replace non load bearing bony structures in the orbital area....
... Rim Implants provide the surgeon ... augmentation of the inferior and ... or secondary rim repair. The ... projection and extends around the ...
... Round handle. Divides nucleus for phacoemulsification. Nuclear ... any hardness can be pre-chopped with pre-chop ... nuclear fragments is rapid. Risk of rupturing ... ultra sound time and minimal movement of ...
Medicine Products: